This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2012 Jan;18(1 Suppl):S92-100.

doi: 10.1016/j.bbmt.2011.10.020.

Neuroblastoma: issues in transplantation

Stephan A Grupp¹, Shahab Asgharzadeh, Gregory A Yanik

Affiliations

PMID: 22226119
PMCID: PMC3260463
DOI: 10.1016/j.bbmt.2011.10.020

Review

Neuroblastoma: issues in transplantation

Stephan A Grupp et al. Biol Blood Marrow Transplant. 2012 Jan.

. 2012 Jan;18(1 Suppl):S92-100.

doi: 10.1016/j.bbmt.2011.10.020.

Authors

Stephan A Grupp¹, Shahab Asgharzadeh, Gregory A Yanik

Affiliation

¹ Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA. grupp@email.chop.edu

PMID: 22226119
PMCID: PMC3260463
DOI: 10.1016/j.bbmt.2011.10.020

No abstract available

PubMed Disclaimer

Figures

Figure 1
Chemical structure of ¹³¹I-metaiodobenzylguanidine and norepinephrine.

Figure 2
¹²³I-mIBG scintigraphy. Extensive mIBG avid disease in cranium, orbits, sino-facial region, bilateral humeri, and sternum.

Figure 3
Phase I study of 131I-mIBG with CEM chemotherapy and autologous stem cell rescue for patients with refractory neuroblastoma. Event free and overall survival. Matthay KK et al. JCO 2006;24: 500–506.

See this image and copyright information in PMC

Similar articles

Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma.
Matthay KK. Matthay KK. Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S21-4. Bone Marrow Transplant. 1996. PMID: 8971402 Clinical Trial.
131I-Metaiodobenzylguanidine conditioning regimen in children with neuroblastoma undergoing stem cell transplantation.
Atas E, Kesik V, Kismet E, Koseoglu V. Atas E, et al. Pediatr Transplant. 2013 Jun;17(4):407-8. doi: 10.1111/petr.12087. Pediatr Transplant. 2013. PMID: 23692603 No abstract available.
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B. Berthold F, et al. Lancet Oncol. 2005 Sep;6(9):649-58. doi: 10.1016/S1470-2045(05)70291-6. Lancet Oncol. 2005. PMID: 16129365 Clinical Trial.
Retinoic Acid for High-risk Neuroblastoma Patients after Autologous Stem Cell Transplantation - Cochrane Review.
Peinemann F, van Dalen EC, Berthold F. Peinemann F, et al. Klin Padiatr. 2016 Apr;228(3):124-9. doi: 10.1055/s-0042-101169. Epub 2016 Mar 24. Klin Padiatr. 2016. PMID: 27011226 Review. English.
Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma.
Matthay KK. Matthay KK. Pediatr Transplant. 1999;3 Suppl 1:72-7. doi: 10.1034/j.1399-3046.1999.00070.x. Pediatr Transplant. 1999. PMID: 10587975 Review.

See all similar articles

Cited by

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK. Kushner BH, et al. Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393. Oncotarget. 2016. PMID: 26623730 Free PMC article.
MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-G_D2 immunotherapy.
Kushner BH, LaQuaglia MP, Modak S, Wolden SL, Basu EM, Roberts SS, Kramer K, Yataghene K, Cheung IY, Cheung NV. Kushner BH, et al. Oncotarget. 2017 Aug 24;8(56):95293-95302. doi: 10.18632/oncotarget.20513. eCollection 2017 Nov 10. Oncotarget. 2017. PMID: 29221128 Free PMC article.
Neuroblastoma: developmental biology, cancer genomics and immunotherapy.
Cheung NK, Dyer MA. Cheung NK, et al. Nat Rev Cancer. 2013 Jun;13(6):397-411. doi: 10.1038/nrc3526. Nat Rev Cancer. 2013. PMID: 23702928 Free PMC article. Review.
Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
Talleur AC, Triplett BM, Federico S, Mamcarz E, Janssen W, Wu J, Shook D, Leung W, Furman WL. Talleur AC, et al. Biol Blood Marrow Transplant. 2017 Nov;23(11):1910-1917. doi: 10.1016/j.bbmt.2017.07.011. Epub 2017 Jul 18. Biol Blood Marrow Transplant. 2017. PMID: 28733263 Free PMC article. Clinical Trial.
Cancer stem cells in neuroblastoma therapy resistance.
Aravindan N, Jain D, Somasundaram DB, Herman TS, Aravindan S. Aravindan N, et al. Cancer Drug Resist. 2019 Dec 19;2(4):948-967. doi: 10.20517/cdr.2019.72. Epub 2019 Nov 11. Cancer Drug Resist. 2019. PMID: 31867574 Free PMC article.

References

1. Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol. 2005;23:8819–8827. - PubMed
1. Simon T, Spitz R, Faldum A, Hero B, Berthold F. New definition of low-risk neuroblastoma using stage, age and 1p and MYCN status. J Pediatr Hematol Oncol. 2004;26:791–796. - PubMed
1. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol. 2000;18:2567–2575. - PubMed
1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165–1173. - PubMed
1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–2120. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information